aMT
aMT properties
Synonyme: alpha-méthyltryptamine
Numéro CAS : 299-26-3
Formule: C11H14N2
Masse molaire: 174.247 g mol−1
Pureté: >98%
€34.95 – €499.95Gamme de prix : €34.95 à €499.95
* Les informations présentées sur cette page constituent un résumé et ne couvrent pas toutes les informations disponibles sur ce médicament. Elles ne couvrent pas toutes les utilisations, posologies, précautions, interactions médicamenteuses ni les effets indésirables possibles, et ne sauraient se substituer à l'expertise et au jugement de votre professionnel de la santé.
AMT (Alpha-Methyltryptamine) – Scientific Product Description
General Information
Substance Name: Alpha-Methyltryptamine (AMT)
Chemical Class: Tryptamine derivative
Statut: Research chemical
Dosage: Varies (10-50mg for research purposes)
Form: Powder or pellets (depending on availability)
Propriétés pharmacologiques
AMT is a monoamine alkaloid with a unique mechanism of action that both:
Serotonergic (5-HT₂A agonism)
Dopaminergic (dopamine reuptake inhibition)
Exhibits noradrenergic effects
Potential Research Areas
1. Neuropsychological Examination
Influence on perceptual processing
Modulation of cognitive flexibility
Effects on creative thinking
2. Behavioral Science Studies
Social interaction patterns
Emotional processing mechanisms
Motivation and reward systems
3. Theoretical Applications
Possible antidepressant effects (preclinical study)
Impact on sleep architecture
Neuroplastic changes
Dosage & Protocol
Research dose range:
Faible dose : 10-20mg
Dose moyenne : 20-35mg
Forte dose : 35-50mg
Time lapse:
Onset of effects: 45-90 minutes
Peak performance: 3-5 hours
Total duration: 8-12 hours
Safety aspects
Side effects
Increased body temperature
Tachycardia
Mydriasis
Possible gastrointestinal discomfort
Contraindications
Combination with MAO inhibitors
Cardiovascular diseases
Psychiatric history
Laboratory analysis
Pureté: ≥97% (HPLC)
Stability: Store in a cool, dry place (<25°C)
Impurities: <0.5% (GC-MS analysis)
Statut juridique
Netherlands: Opium Act Schedule I
Belgium: Prohibited substance
EU: Under EU NPS legislation
Research protocols
Start low: 10mg initial test dose
Pharmaceutical monitoring: Blood pressure and temperature measurement
Intervals: Minimum 7 days between experiments
Important Warnings
❌ Pas de consommation humaine
❌ Do not combine with other psychoactives
❌ Avoid prolonged or frequent use
This product is intended solely for in vitro research et scientific study under controlled laboratory conditions.
Buvards artistiques 1cP-LSD 150 MCG Granulés O-DSMT 50 mg buvards 1V-LSD 150 MCG 6-CL-ADBA
